166 related articles for article (PubMed ID: 37073741)
21. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study.
Zsiros J; Brugieres L; Brock P; Roebuck D; Maibach R; Zimmermann A; Childs M; Pariente D; Laithier V; Otte JB; Branchereau S; Aronson D; Rangaswami A; Ronghe M; Casanova M; Sullivan M; Morland B; Czauderna P; Perilongo G;
Lancet Oncol; 2013 Aug; 14(9):834-42. PubMed ID: 23831416
[TBL] [Abstract][Full Text] [Related]
22. Prognostic implications of serum alpha-fetoprotein response during treatment of hepatoblastoma.
Koh KN; Park M; Kim BE; Bae KW; Kim KM; Im HJ; Seo JJ
Pediatr Blood Cancer; 2011 Oct; 57(4):554-60. PubMed ID: 21370433
[TBL] [Abstract][Full Text] [Related]
23. Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
Defachelles AS; Bogart E; Casanova M; Merks JHM; Bisogno G; Calareso G; Gallego Melcon S; Gatz SA; Le Deley MC; McHugh K; Probst A; Rocourt N; van Rijn RR; Wheatley K; Minard-Colin V; Chisholm JC
J Clin Oncol; 2021 Sep; 39(27):2979-2990. PubMed ID: 34343032
[TBL] [Abstract][Full Text] [Related]
24. Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee.
Trobaugh-Lotrario A; Katzenstein HM; Ranganathan S; Lopez-Terrada D; Krailo MD; Piao J; Chung N; Randazzo J; Malogolowkin MH; Furman WL; McCarville EB; Towbin AJ; Tiao GM; Dunn SP; Langham MR; McGahren ED; Feusner J; Rodriguez-Galindo C; Meyers RL; O'Neill AF; Finegold MJ
J Clin Oncol; 2022 Feb; 40(5):459-467. PubMed ID: 34874751
[TBL] [Abstract][Full Text] [Related]
25. The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor.
Liu KX; Collins NB; Greenzang KA; Furutani E; Campbell K; Groves A; Mullen EA; Shusterman S; Spidle J; Marcus KJ; Weil BR; Weldon CB; Frazier AL; Janeway KA; O'Neill AF; Mack JW; DuBois SG; Shulman DS
Pediatr Blood Cancer; 2020 Oct; 67(10):e28559. PubMed ID: 32686305
[TBL] [Abstract][Full Text] [Related]
26. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
Häberle B; Bode U; von Schweinitz D
Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
[TBL] [Abstract][Full Text] [Related]
27. Redefining the role of doxorubicin for the treatment of children with hepatoblastoma.
Malogolowkin MH; Katzenstein HM; Krailo M; Chen Z; Quinn JJ; Reynolds M; Ortega JA
J Clin Oncol; 2008 May; 26(14):2379-83. PubMed ID: 18467729
[TBL] [Abstract][Full Text] [Related]
28. Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma--a report from the German Cooperative Pediatric Liver Tumor Study HB-89.
von Schweinitz D; Hecker H; Harms D; Bode U; Weinel P; Bürger D; Erttmann R; Mildenberger H
J Pediatr Surg; 1995 Jun; 30(6):845-52. PubMed ID: 7545228
[TBL] [Abstract][Full Text] [Related]
29. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma.
Malogolowkin MH; Katzenstein H; Krailo MD; Chen Z; Bowman L; Reynolds M; Finegold M; Greffe B; Rowland J; Newman K; Womer RB; London WB; Castleberry RP
J Clin Oncol; 2006 Jun; 24(18):2879-84. PubMed ID: 16782927
[TBL] [Abstract][Full Text] [Related]
30. Feasibility of combining temsirolimus to vincristine, dactinomycin, cyclophosphamide, and vincristine and irinotecan chemotherapy for children with intermediate-risk rhabdomyosarcoma: A report from Children's Oncology Group.
Oberoi S; Qumseya A; Xue W; Harrison DJ; Rudzinski ER; Wolden SL; Dasgupta R; Venkatramani R; Gupta AA
Pediatr Blood Cancer; 2023 May; ():e30436. PubMed ID: 37243336
[TBL] [Abstract][Full Text] [Related]
31. Improved long-term survival with preoperative chemotherapy for hepatoblastoma.
Ehrlich PF; Greenberg ML; Filler RM
J Pediatr Surg; 1997 Jul; 32(7):999-1002; discussion 1002-3. PubMed ID: 9247221
[TBL] [Abstract][Full Text] [Related]
32. High Dose Chemotherapy with Autologous Stem Cell Transplantation in Hepatoblastoma does not Improve Outcome. Results of the GPOH Study HB99.
Häberle B; Maxwell R; Schweinitz DV; Schmid I
Klin Padiatr; 2019 Nov; 231(6):283-290. PubMed ID: 31645068
[TBL] [Abstract][Full Text] [Related]
33. Hepatoblastoma presenting with lung metastases: treatment results of the first cooperative, prospective study of the International Society of Paediatric Oncology on childhood liver tumors.
Perilongo G; Brown J; Shafford E; Brock P; De Camargo B; Keeling JW; Vos A; Philips A; Pritchard J; Plaschkes J
Cancer; 2000 Oct; 89(8):1845-53. PubMed ID: 11042582
[TBL] [Abstract][Full Text] [Related]
34. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Weigel BJ; Lyden E; Anderson JR; Meyer WH; Parham DM; Rodeberg DA; Michalski JM; Hawkins DS; Arndt CA
J Clin Oncol; 2016 Jan; 34(2):117-22. PubMed ID: 26503200
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapeutic approaches for newly diagnosed hepatoblastoma: past, present, and future strategies.
Trobaugh-Lotrario AD; Katzenstein HM
Pediatr Blood Cancer; 2012 Nov; 59(5):809-12. PubMed ID: 22648979
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL).
Zsíros J; Brugières L; Brock P; Roebuck D; Maibach R; Child M; Morland B; Casanova M; Pariente D; Paris C; de Camargo B; Ronghe M; Zimmermann A; Plaschkes J; Czauderna P; Perilongo G
Eur J Cancer; 2012 Dec; 48(18):3456-64. PubMed ID: 22835780
[TBL] [Abstract][Full Text] [Related]
37. [Outcome of hepatoblastoma: experience with 63 patients received chemotherapy with the regimen C5V].
Liu G; Liu B; Li K; Dong K; Xiao X
Zhonghua Er Ke Za Zhi; 2015 Feb; 53(2):119-23. PubMed ID: 25876687
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group.
Mascarenhas L; Lyden ER; Breitfeld PP; Walterhouse DO; Donaldson SS; Paidas CN; Parham DM; Anderson JR; Meyer WH; Hawkins DS
J Clin Oncol; 2010 Oct; 28(30):4658-63. PubMed ID: 20837952
[TBL] [Abstract][Full Text] [Related]
39. Fibrolamellar hepatocellular carcinoma in children and adolescents.
Katzenstein HM; Krailo MD; Malogolowkin MH; Ortega JA; Qu W; Douglass EC; Feusner JH; Reynolds M; Quinn JJ; Newman K; Finegold MJ; Haas JE; Sensel MG; Castleberry RP; Bowman LC
Cancer; 2003 Apr; 97(8):2006-12. PubMed ID: 12673731
[TBL] [Abstract][Full Text] [Related]
40. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology.
von Schweinitz D; Byrd DJ; Hecker H; Weinel P; Bode U; Bürger D; Erttmann R; Harms D; Mildenberger H
Eur J Cancer; 1997 Jul; 33(8):1243-9. PubMed ID: 9301450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
